E

Editas Medicine

CRISPR-based gene editing therapeutics developer

Associate Director - Lipid Process Chemistry

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$185k - $200kIn-person

About the Job

Requirements

  • A Ph.D. in Organic Chemistry, Synthetic Chemistry, or a closely related discipline and at least 6–7 years of direct experience in an established lipid synthesis or LNP therapeutics company or a similar industry, such as mRNA therapeutics, oligonucleotides, gene therapy, or drug delivery biotechnology platforms; alternatively, a BS or MS in Organic Chemistry, Synthetic Chemistry, or a closely related discipline and at least 10–12 years of such direct experience.
  • Expertise in multi-step organic synthesis, scalable purification, and analytical characterization using nuclear magnetic resonance (NMR), liquid chromatography–mass spectrometry (LC-MS), and high-performance liquid chromatography (HPLC) for custom lipids or advanced small-molecule raw materials.
  • Success managing external contract development and manufacturing organization (CDMO) partners through process optimization, technology transfer, and clinical supply production.
  • A track record of managing technical teams and partnering with cross-functional stakeholders to achieve organizational objectives.
  • Deep understanding of current Good Manufacturing Practices (cGMP), International Council for Harmonisation (ICH) guidelines, and regulatory expectations for clinical-stage drug substances.

Responsibilities

  • Serve as the technical lead and primary Chemistry, Manufacturing, and Controls (CMC) contact for CDMO partners supporting development, scale-up, and GMP manufacture of novel ionizable, helper, and PEGylated lipids.
  • Provide technical oversight of outsourced manufacturing campaigns, including review and approval of protocols, master and executed batch records, deviations, and change controls.
  • Act as Person-in-Plant (PIP) during critical engineering and clinical manufacturing runs at CDMO facilities.
  • Identify process and scale-up risks and lead troubleshooting and root-cause investigations for manufacturing deviations and out-of-specification (OOS) results.
  • Direct external partners in route scouting, process optimization, and scale-up to enable safe, efficient, and cost-effective lipid production.
  • Partner with Research to drive discovery, design, and sourcing of novel lipid constructs supporting pipeline programs and targeted delivery strategies.
  • Develop scalable lipid isolation and purification processes using chromatography, crystallization, tangential flow filtration (TFF), and related technologies.
  • Apply design of experiments (DoE) and quality by design (QbD) principles to define critical process parameters, material specifications, and process controls.
  • Author and execute technology transfer packages to transition processes from research and development to current Good Manufacturing Practice (cGMP) manufacturing.
  • Author and review lipid excipients for regulatory submissions, including Investigational New Drug (IND) applications, Investigational Medicinal Product Dossiers (IMPDs), and Clinical Trial Applications (CTAs).
  • Collaborate with Formulation, Analytical Development, Quality, Manufacturing, and Supply Chain teams to integrate lipid raw materials into drug product manufacturing.
  • Define and assess critical quality attributes (CQAs) and drive analytical and process strategies that support product quality, safety, and efficacy.

Desired Qualifications

  • Prior experience preparing for or participating in Chemistry, Manufacturing, and Controls (CMC) health authority interactions or regulatory audits.
  • A track record of taking a novel lipid from discovery candidate nomination through successful Phase I/II clinical trial GMP supply.
  • Experience implementing Process Analytical Technology (PAT) tools or continuous flow chemistry for lipid manufacturing.
  • An active presence and network in the Boston/Cambridge biotechnology ecosystem.

About the Company

Editas Medicine

CRISPR-based gene editing therapeutics developer

Editas Medicine develops therapies using CRISPR gene-editing to treat serious diseases. The company advances a pipeline of genomic medicines by discovering, developing, manufacturing, and aiming to commercialize these gene-editing treatments. CRISPR allows scientists to modify DNA in cells to correct genetic defects, and Editas combines this approach with clinical development to bring potential medicines to patients. Unlike firms that focus on other biotechnologies, Editas emphasizes a full drug-development cycle centered on CRISPR-based genomic medicines and partnerships to expand its reach. The company’s goal is to deliver durable, transformative treatments that improve patient outcomes worldwide by moving candidates from discovery through trials to potential approval and commercialization.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Editas Medicine

See more jobs